Indeed, as result of better understanding of the immune pathways involved in enthesitis, we are witnessing novel treatment advances that offer new opportunities to improve clinical entheseal disease including IL-23 and IL-17 blockers as biological agents, and small molecules such as PDE4 inhibitors and JAK inhibition [12–14]. This evidence concerns the gene PDE4A and enthesitis.